R&D channel feed

Scoop: Roche scraps one of two schiz­o­phre­nia PhII tri­als af­ter fail­ing the pri­ma­ry end­point

3 years ago
Pharma

Roivant chops sick­le cell gene ther­a­py, der­ma­tol­ogy drugs to fo­cus on 'high­er val­ue pro­ject­s'

3 years ago

Still in pre­clin­i­cal test­ing for ear gene ther­a­pies, Deci­bel touts small snap­shot of chemo-in­duced hear­ing loss drug

3 years ago

Af­ter a 5-year re­peat PhI­II so­journ, Lund­beck and Ot­su­ka say they're fi­nal­ly ready to pur­sue OK to use Rex­ul­ti against Alzheimer's ag­i­ta­tion

3 years ago

Take­da, Ar­row­head spot­light da­ta from small tri­al show­ing RNAi works in a rare liv­er con­di­tion

3 years ago

FDA places par­tial clin­i­cal hold on David Hung biotech af­ter cer­tain can­cer pa­tients ex­pe­ri­ence eye in­flam­ma­tion

3 years ago
FDA+

Re­lay builds out case for an­ti-FGFR drug, shoot­ing for first ac­cel­er­at­ed ap­proval on 'mo­tion-based' drug dis­cov­ery plat­form

3 years ago

Scoop: Boehringer qui­et­ly shut­ters a PhII for one of its top drugs — now un­der re­view

3 years ago

GSK says its drug for chron­ic hep B could ‘lead to a func­tion­al cure’ — but will it be alone or in com­bi­na­tion?

3 years ago

In­tel­li­a's CRISPR pro­gram that ed­its genes di­rect­ly in pa­tients shows dura­bil­i­ty in AT­TR amy­loi­do­sis

3 years ago
Cell/Gene Tx

New re­port de­tails se­quence of events lead­ing up to death of man who re­ceived pig heart trans­plant

3 years ago
Pharma

Sanofi, GSK tout 72% Omi­cron ef­fi­ca­cy in PhI­II tri­al of next-gen, bi­va­lent shot — with an eye to year-end roll­out

3 years ago
Coronavirus

CAR-T in, IPF drug out: Gala­pa­gos bails on biotech part­ner­ship amid pipeline re­vamp

3 years ago
Deals

In trou­bled Hunt­ing­ton’s space, uniQure’s gene ther­a­py shows ear­ly promise

3 years ago
Cell/Gene Tx

Xenon jumps on pos­i­tive da­ta-to-im­me­di­ate pub­lic of­fer­ing train to bankroll PhI­II epilep­sy study

3 years ago
Financing

No­var­tis pledges $250M in R&D fund­ing for ne­glect­ed trop­i­cal dis­eases, malar­ia

3 years ago

Gal­der­ma drug pass­es PhI­II in rare skin dis­ease, set­ting the stage for ap­proval re­quest

3 years ago

Mer­ck out­flanks Pfiz­er's 20-va­lent shot with pneu­mo­coc­cal vac­cine ap­proval for kids

3 years ago
FDA+

Take­da to fur­ther ce­ment pres­ence in Cam­bridge, MA bio­phar­ma hub with 600,000-square-foot R&D cen­ter

3 years ago
Pharma

Athi­ra’s al­ter­na­tive Alzheimer’s ap­proach runs in­to a PhII brick wall

3 years ago

Big da­ta meets Big Phar­ma: Pfiz­er buys re­al-time pa­tient re­sults in col­lab­o­ra­tion with Tru­ve­ta

3 years ago

PTC of­fers its best case for a con­tro­ver­sial Duchenne MD PhI­II. But key fail­ures spark fresh doubts of suc­cess at FDA

3 years ago

PhI­II dead end for celi­ac drug crush­es pen­ny stock biotech

3 years ago

Mer­ck touts new da­ta for break­through pneu­mo­coc­cal vac­cine as it heads to PhI­II tri­als

3 years ago
Pharma
First page Previous page 131132133134135136137 Next page Last page
A service from the Financial Times